摘要
目的 观察国产重组链激酶 (r SK)对下肢急性深静脉血栓形成的疗效和安全性。方法 3 0例下肢急性深静脉血栓形成患者随机分为r SK治疗组 (A组 )和UK治疗组 (B组 ) ,观察疗效的临床指标、过敏反应和出血等并发症。结果 A组总有效率 ( 93 .3 % )显著高于B组 ( 66.7% ) ;A组引起的凝血和纤溶系统变化均比B组明显 ,不良反应率也较B组高 ,但差异均无显著意义。结论 r SK治疗下肢急性深静脉血栓形成是安全和有效的 。
Purpose: To evaluate the efficacy and safety of intravenous recombinant streptokinase (r-SK) in treatment of patients with acute deep veinous thrombosis of the lower limbs (ADVT). Methods: Thirty patients with ADVT were divided into two groups randomized. Patients who receive r-SK (n = 15) were catalogued as group A and UK (n = 15) as group B. Clinical criteria of efficacy and the complication of hypersensitivity or bleeding were evaluated. Results: The total efficiency rate for group A was 93.3%, while the group B was 66.7% (P>0.05). Group A shew more significant effects in fibrinolytic and coagulation system. The incidence of hypotension and bleeding complication were a little bit higher in group A than in group B and were also not significantly (P>0.05). Conclusions: China-made r-SK is a safe and effective thrombolytic agent in treatment of patients with ADVT.
出处
《复旦学报（医学版）》
EI
CAS
CSCD
北大核心
2003年第1期82-83,共2页
Fudan University Journal of Medical Sciences
